Navigation Links
Biotrial, a Leading Provider of Drug Development Services, Has Completed its Acquisition of Warnex Bioanalytical Services Division

(PRWEB) February 22, 2013

The acquisition of the Warnex Bioanalytical Services division allows Biotrial to broaden its drug development services to its international clients, giving them access to the full spectrum of Bioanalytical services to support preclinical and clinical development, including generics product development. To complement the service offering, Warnex clients now have access to the large range of existing Biotrial drug development services.

The new Biotrial addition includes: a team of highly experienced experts including a staff of over 70, more than 250 validated assays, 25 000 sq. ft. cutting edge laboratories and work stations, over 20 Mass Spectrometers and a validated Watson® LIMS.

BBS services have a SCC certification; have been audited by the FDA and AGES regulatory agencies. Services offered include: method development & validation, preclinical, bioavailability and bioequivalence studies, as well as therapeutic drug monitoring.

Jean-Marc Gandon, Pharm.D., President & CEO of Biotrial, says: “We have been looking for many years to find the right partner to complement our offer with sample analysis so that our customers could benefit from a full package in their process of developing new drugs or generics. Because of its ability to meet the growing needs of the pharmaceutical industry and to use the latest technology Warnex became an obvious choice. Biotrial is committed to continue providing the excellent service and quality of science for which the Montreal site is known for, by continuing its investment in the latest state-of-the-art equipment.”

Michael Mancini, Ph.D., BBS Inc. President, affirms: “It has been a very smooth transition and we are particularly excited to officially be a part of the Biotrial team. There is no change in management or staff and for us it is ‘business as usual.’ Being a part of such an international and well recognized CRO ensures that we will continue to expand our service offering as we have been doing for so many years.”

With the Bioanalytical acquisition Biotrial continues its expansion into the North American market which, will be complemented by the opening of an additional Clinical Unit in New Jersey later this year.

About Biotrial
Founded in 1989, Biotrial is a leading CRO specialized in Early Development with a large range of services from Non-Clinical Pharmacology, Phase I studies, Phase II-IV Trial Management, Bioanalytical analysis, Oncology, Data Management, Biostatistics, ECG & Imaging Core Lab (QT/QTc Trials, Psychometric Testing, Imaging, EEG/PSG Assessment), Regulatory Affairs to Medical Writing.

Based in France, Belgium, the United Kingdom, Canada and the United States, Biotrial performs hundreds of studies a year and offers tailor-made solutions to Biotech and Pharmaceutical companies.

For further information please contact Anne Peron at [+33] (0)2 99 599 191 or visit [

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Plunketts Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
2. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
3. ViaCytes Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012
4. Agency Take-up Soars of Agnitios Leading Pull Marketing Platform for the Healthcare Industry
5. LATISTA Announces Next-Generation iPad App 2.0 for Construction with Industry Leading Innovations
6. The Leading Edge Of Medical Innovation: New Prenatal Genetic Tests Use Moms Blood To Learn About Her Baby
7. Crisalix Awarded as a Leading Life Science Company that is Revolutionizing the Medical Industry
8. Speech and Language Therapy Jobs and Biomedical Science Jobs - Medicspro Leading the way for Medical Recruitment Agencies in the UK
9. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
10. A leading Massachusetts-based IT and Life Sciences staffing and consulting firm has opened two new offices in the Ohio Valley
11. Maker of leading in-home HIV test encourages testing
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... in cat and human plaque and pave the way for ... health problems in cats     ... the most commonly diagnosed health problems in cats, yet relatively ... until now. Two collaborative studies have been conducted by researchers ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the ... other AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. ...
Breaking Biology Technology:
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
(Date:10/23/2015)... 2015 Research and Markets ( ) ... Recognition Biometrics Market 2015-2019" report to their offering. ... The global voice recognition biometrics market to grow at ... --> --> The report, Global ... on an in-depth market analysis with inputs from industry ...
(Date:10/22/2015)...  Synaptics (NASDAQ: SYNA ), a leading developer of human ... September 30, 2015. --> --> ... 66 percent over the comparable quarter last year to $470.0 million. ... million, or $0.62 per diluted share. --> ... of fiscal 2016 grew 39 percent over the prior year period ...
Breaking Biology News(10 mins):